| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA4243377
Max Phase: Preclinical
Molecular Formula: C19H22N2O3S
Molecular Weight: 358.46
Molecule Type: Small molecule
Associated Items:
Representations
Canonical SMILES: CCCN(c1ccccc1)S(=O)(=O)c1ccc(N2CCCC2=O)cc1
Standard InChI: InChI=1S/C19H22N2O3S/c1-2-14-21(17-7-4-3-5-8-17)25(23,24)18-12-10-16(11-13-18)20-15-6-9-19(20)22/h3-5,7-8,10-13H,2,6,9,14-15H2,1H3
Standard InChI Key: FIGIKTDJBDBDIR-UHFFFAOYSA-N
Associated Targets(Human)
MCF7 (126967 Activities)
MDA-MB-231 (73002 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
TP53 Tchem Cellular tumor antigen p53 (48468 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 358.46 | Molecular Weight (Monoisotopic): 358.1351 | AlogP: 3.42 | #Rotatable Bonds: 6 |
| Polar Surface Area: 57.69 | Molecular Species: NEUTRAL | HBA: 3 | HBD: 0 |
| #RO5 Violations: 0 | HBA (Lipinski): 5 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: | CX Basic pKa: | CX LogP: 2.89 | CX LogD: 2.89 |
| Aromatic Rings: 2 | Heavy Atoms: 25 | QED Weighted: 0.79 | Np Likeness Score: -1.84 |
References
| 1. Okolotowicz KJ, Dwyer M, Ryan D, Cheng J, Cashman EA, Moore S, Mercola M, Cashman JR.. (2018) Novel tertiary sulfonamides as potent anti-cancer agents., 26 (15): [PMID:30075999] [10.1016/j.bmc.2018.07.042] |
Source
Source(1):